Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Legal & General Group Plc

Legal & General Group Plc lifted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 1,577.6% during the 4th quarter, Holdings Channel reports. The fund owned 17,682 shares of the biotechnology company’s stock after buying an additional 16,628 shares during the quarter. Legal & General Group Plc’s holdings in Ascendis Pharma A/S were worth $2,433,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ASND. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S during the third quarter worth about $30,000. Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after buying an additional 328 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $203,000.

Ascendis Pharma A/S Price Performance

ASND opened at $160.45 on Friday. The stock has a market capitalization of $9.78 billion, a price-to-earnings ratio of -22.60 and a beta of 0.54. The business has a fifty day moving average price of $153.64 and a 200 day moving average price of $138.68. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ASND shares. UBS Group began coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price for the company. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. JPMorgan Chase & Co. increased their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. The Goldman Sachs Group boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, Cantor Fitzgerald increased their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $204.67.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.